Abstract
Most of the 2022 mpox outbreaks in high income countries, which predominantly affected men who have sex with men, peaked less than two months after detection. To stop the outbreaks, people were encouraged to limit new sex partners, take up any offers for smallpox vaccination, and self-isolate. The relative contributions of each of these strategies to outbreak reduction are hard to know. To consider the potential relative efficacy of each of these measures individually, we constructed agent-based models using plausible partnership counts, reasonable behaviour choices and published information about smallpox vaccination uptake rates in the UK context during 2022. Compared to a baseline, no intervention scenario, partner reduction was more effective at preventing generation of secondary cases than the vaccine rollout at the speed that the smallpox vaccine rollout occurred in the UK in 2022. These findings suggest that partner reduction by the most affected community rather than pharmaceutical intervention was largely to credit for causing case numbers to peak as early as they did.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response at Kings College London in partnership with the UK Health Security Agency (UKHSA) and collaboration with the University of East Anglia (UEA). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, UEA, the Department of Health or UKHSA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
